1
|
Brodeur GM: Neuroblastoma: biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Vermeulen L, de Sousa e Melo F, Richel DJ
and Medema JP: The developing cancer stem-cell model: clinical
challenges and opportunities. Lancet Oncol. 13:e83–e89. 2012.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Müller V, Alix-Panabières C and Pantel K:
Insights into minimal residual disease in cancer patients:
implications for anti-cancer therapies. Eur J Cancer. 46:1189–1197.
2010.PubMed/NCBI
|
8
|
Mordant P, Loriot Y, Lahon B, et al:
Minimal residual disease in solid neoplasia: new frontier or
red-herring? Cancer Treat Rev. 38:101–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hansford LM, McKee AE, Zhang L, et al:
Neuroblastoma cells isolated from bone marrow metastases contain a
naturally enriched tumor-initiating cell. Cancer Res.
67:11234–11243. 2007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Coulon A, Flahaut M, Mühlethaler-Mottet A,
et al: Functional sphere profiling reveals the complexity of
neuroblastoma tumor-initiating cell model. Neoplasia. 13:991–1004.
2011.PubMed/NCBI
|
11
|
Lin H, Balic M, Zheng S, Datar R and Cote
RJ: Disseminated and circulating tumor cells: role in effective
cancer management. Crit Rev Oncol Hematol. 77:1–11. 2011.
View Article : Google Scholar : PubMed/NCBI
|
12
|
van der Velden VHJ, Cazzaniga G, Schrauder
A, et al: Analysis of minimal residual disease by Ig/TCR gene
rearrangements: guidelines for interpretation of real-time
quantitative PCR data. Leukemia. 21:604–611. 2007.PubMed/NCBI
|
13
|
Flohr T, Schrauder A, Cazzaniga G, et al:
Minimal residual disease-directed risk stratification using
real-time quantitative PCR analysis of immunoglobulin and T-cell
receptor gene rearrangements in the international multicenter trial
AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Leukemia. 22:771–782. 2008. View Article : Google Scholar
|
14
|
Kågedal B: Detecting minimal residual
disease in neuroblastoma: still a ways to go. Clin Chem.
55:1268–1270. 2009.PubMed/NCBI
|
15
|
Stutterheim J, Zappeij-Kannegieter L,
Versteeg R, Caron HN, van der Schoot CE and Tytgat GAM: The
prognostic value of fast molecular response of marrow disease in
patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer.
47:1193–1202. 2011.PubMed/NCBI
|
16
|
Yáñez Y, Grau E, Oltra S, et al: Minimal
disease detection in peripheral blood and bone marrow from patients
with non-metastatic neuroblastoma. J Cancer Res Clin Oncol.
137:1263–1272. 2011.PubMed/NCBI
|
17
|
Burchill SA, Bradbury FM, Smith B, Lewis
IJ and Selby P: Neuroblastoma cell detection by reverse
transcriptase-polymerase chain reaction (RT-PCR) for tyrosine
hydroxylase mRNA. Int J Cancer. 57:671–675. 1994. View Article : Google Scholar
|
18
|
Miyajima Y, Kato K, Numata SI, Kudo K and
Horibe K: Detection of neuroblastoma cells in bone marrow and
peripheral blood at diagnosis by the reverse
transcriptase-polymerase chain reaction for tyrosine hydroxylase
mRNA. Cancer. 75:2757–2761. 1995. View Article : Google Scholar : PubMed/NCBI
|
19
|
Kuçi Z, Seitz G, Kuçi S, et al: Pitfalls
in detection of contaminating neuroblastoma cells by tyrosine
hydroxylase RT-PCR due to catecholamine-producing hematopoietic
cells. Anticancer Res. 26:2075–2080. 2006.PubMed/NCBI
|
20
|
Viprey VF, Corrias MV, Kågedal B, et al:
Standardisation of operating procedures for the detection of
minimal disease by QRT-PCR in children with neuroblastoma: quality
assurance on behalf of SIOPEN-R-NET. Eur J Cancer. 43:341–350.
2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
Stutterheim J, Gerritsen A,
Zappeij-Kannegieter L, et al: PHOX2B is a novel and specific marker
for minimal residual disease testing in neuroblastoma. J Clin
Oncol. 26:5443–5449. 2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Viprey VF, Lastowska MA, Corrias MV,
Swerts K, Jackson MS and Burchill SA: Minimal disease monitoring by
QRT-PCR: guidelines for identification and systematic validation of
molecular markers prior to evaluation in prospective clinical
trials. J Pathol. 216:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Cheung IY, Feng Y, Gerald W and Cheung NK:
Exploiting gene expression profiling to identify novel minimal
residual disease markers of neuroblastoma. Clin Cancer Res.
14:7020–7027. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Stutterheim J, Gerritsen A,
Zappeij-Kannegieter L, et al: Detecting minimal residual disease in
neuroblastoma: the superiority of a panel of real-time quantitative
PCR markers. Clin Chem. 55:1316–1326. 2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Nishimura N, Hartomo TB, Pham TVH, et al:
Epigallocatechin gallate inhibits sphere formation of neuroblastoma
BE(2)-C cells. Environ Health Prev Med. 17:246–251. 2012.
View Article : Google Scholar
|
26
|
Cheung IY and Cheung NK: Quantitation of
marrow disease in neuroblastoma by real-time reverse
transcription-PCR. Clin Cancer Res. 7:1698–1705. 2001.PubMed/NCBI
|
27
|
Stutterheim J, Zappeij-Kannegieter L, Ora
I, et al: Stability of PCR targets for monitoring minimal residual
disease in neuroblastoma. J Mol Diagn. 14:168–175. 2012. View Article : Google Scholar : PubMed/NCBI
|